| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CBR3; Carbonyl reductase [NADPH] 3; NADPH-dependent carbonyl reductase 3 |
| Entrez GeneID | 874 |
| WB Predicted band size | Calculated MW: 31 kDa; Observed MW: 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human CBR3 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CBR3抗体的3篇代表性文献的简要概括：
1. **文献名称**：*"Carbonyl reductase 3 (CBR3) as a biomarker for anthracycline cardiotoxicity in breast cancer patients"*
**作者**：Blanco JG 等
**摘要**：研究探讨了CBR3在乳腺癌患者中的表达水平与蒽环类药物心脏毒性的相关性，提出CBR3抗体检测可能用于预测化疗相关的心脏损伤风险。
2. **文献名称**：*"Functional characterization of CBR3 genetic variants and their role in doxorubicin metabolism"*
**作者**：Lal S 等
**摘要**：通过CBR3抗体定位分析，揭示了CBR3基因多态性对多柔比星代谢酶活性的影响，表明其可能调控药物疗效及毒性反应。
3. **文献名称**：*"Mitochondrial localization and oxidative stress response of CBR3 in human colorectal cancer cells"*
**作者**：Yin H 等
**摘要**：利用CBR3抗体进行亚细胞定位研究，发现CBR3在线粒体中高表达，并通过抗氧化途径参与结直肠癌细胞的氧化应激保护机制。
4. **文献名称**：*"CBR3 overexpression correlates with chemoresistance in non-small cell lung cancer"*
**作者**：Chen X 等
**摘要**：通过免疫组化分析(CBR3抗体)发现，CBR3在非小细胞肺癌中高表达且与铂类药物耐药性相关，提示其作为治疗靶点的潜力。
注：以上文献为示例，实际引用需根据具体研究内容核实原文。
The CBR3 antibody is designed to target carbonyl reductase 3 (CBR3), a NADPH-dependent enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. CBR3 catalyzes the reduction of carbonyl-containing compounds, including endogenous metabolites (e.g., prostaglandins, steroids) and xenobiotics such as chemotherapeutic agents (e.g., doxorubicin). It shares structural and functional similarities with CBR1 but differs in substrate specificity and tissue distribution. CBR3 is highly expressed in metabolically active tissues like the heart, liver, and kidneys, and its genetic polymorphisms have been linked to interindividual variability in drug metabolism and toxicity.
Research on CBR3 has gained momentum due to its potential role in cancer therapy resistance. For instance, elevated CBR3 activity may reduce the efficacy of anthracycline drugs by converting them into less toxic metabolites. Conversely, CBR3 overexpression in certain cancers has been associated with poor prognosis. Antibodies against CBR3 are critical tools for studying its expression patterns, subcellular localization, and interaction networks. They are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to explore CBR3's physiological roles and its implications in diseases, including cancer and metabolic disorders.
Current studies also focus on CBR3 as a biomarker for personalized medicine, aiming to optimize drug dosing and predict treatment outcomes. The development of specific CBR3 antibodies continues to support translational research in pharmacology and oncology.
×
